Dexona

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexona

What is Dexona? A Definitive Overview

Property Description
Active ingredients Dexamethasone, Neomycin
Form Sterile solution (drops)
Pharmacological class Corticosteroid & Aminoglycoside Antibiotic combination
Common use Anti-inflammatory and anti-infective treatment
Origin Synthetic
Rx Status Prescription-only medicine (Rx)

The medicinal preparation known as Dexona is a prescription-only (Rx), fixed-dose combination product specifically formulated as a sterile solution for topical application to the eye or ear. This combination integrates two distinct active pharmaceutical ingredients—the anti-inflammatory agent, Dexamethasone, and the anti-infective agent, Neomycin—placing it within the pharmacological class of a Corticosteroid and Aminoglycoside Antibiotic combination. The components are chemically derived, confirming the product is entirely synthetic.

Classification: A Fixed-Dose Combination

Dexona is defined by its two International Nonproprietary Names (INN): Dexamethasone and Neomycin. This combination is architected to deliver dual therapeutic effects simultaneously, which is an advantage in clinical scenarios where inflammation is either caused by bacteria or carries a high risk of developing a secondary bacterial infection. The presence of Dexamethasone, a potent glucocorticoid, functions to reduce severe local inflammation and suppress the associated immune response. This confirms the medicine's primary role in reducing the symptomatic swelling and redness.

Composition and General Purpose

The composition features Dexamethasone to manage the physical symptoms of local inflammation and Neomycin to exert a bactericidal effect against susceptible organisms. These agents are prepared in a sterile aqueous vehicle, allowing for precise delivery via the topical route, either as ophthalmic or otic drops. The dual-agent structure establishes the medication's overall therapeutic purpose: to provide comprehensive support by simultaneously reducing inflammatory distress and addressing the bacterial load. This approach reflects the convenience and effectiveness of administering both anti-inflammatory and anti-infective agents together. This integrated strategy is vital for the effective resolution of localized conditions in the sensitive tissues of the eye and external ear, differentiating it from single-agent formulations.

Regulatory References

  1. clinically recognized

What side effects are possible with Dexona?

Possible Side Effects and Safety Information

The safety profile for this medicine, a combination of Dexamethasone and Neomycin, is structured by the risks documented for each component, primarily concerning local topical application. Adverse reactions are classified by regulatory authorities based on affected organ systems and frequency.

System-Organ Specific Reactions

The most commonly classified adverse effects pertain to Eye Disorders (from the corticosteroid) and Ear and Labyrinth Disorders (from the aminoglycoside, Neomycin). General Immune System Disorders, such as hypersensitivity and allergic sensitization, are also documented.

Serious Adverse Reactions and Duration-Related Risks

Specific serious adverse reactions are associated with the prolonged use of the corticosteroid component. These include the development of ocular hypertension (glaucoma), which can lead to optic nerve damage and defects in the visual field, and the formation of a posterior subcapsular cataract. Where corneal or scleral thinning is present, use carries the risk of globe perforation.

For otic use, the primary serious risk is irreversible hearing loss (ototoxicity), which is explicitly associated with the Neomycin component when the medicine is used in the presence of a perforated tympanic membrane. Generalized severe allergic reactions, such as anaphylaxis, are also listed.

Population and Constraint Notes

Official prescribing information notes that use during pregnancy should occur only if the potential benefit outweighs the risk, and infants should be monitored for hypoadrenalism. The medicine is contraindicated in specific pre-existing infections, including most active viral diseases (such as herpes simplex keratitis), mycobacterial, and fungal diseases of the ocular structure due to the steroid component's effect on host response. The perforated tympanic membrane is a definitive safety constraint for otic administration.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Dexamethasone/Neomycin primarily through the risks associated with excessive or prolonged topical application. Acute overdose from a single large application is generally not expected to cause life-threatening systemic toxicity.

Overdose manifestations stemming from repeated instillation or long-term high exposure may include the development of ocular high-pressure, lens opacification, superficial keratitis, and delayed healing of ocular tissues. Serious long-term outcomes of this chronic exposure include potential damage to the optic nerve and visual field defects. Furthermore, intensive long-term therapy carries the risk of sufficient systemic absorption to cause Cushing's syndrome or adrenal suppression.

Immediate medical attention is required if the medication is accidentally swallowed or ingested, as mandated by regulatory labeling. For a simple topical overdose, the procedural step described is to flush the affected eye(s) with lukewarm water. The risk of corticosteroid-induced ocular hypertension is specifically noted to be greater in children during prolonged use. Management of overdose is symptomatic and supportive, as no specific antidote is officially documented.

Therapeutic Uses of Dexona

This medication is applied in managing symptoms related to inflammatory or irritative states across several therapeutic domains. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Relief from Inflammation and Systemic Discomfort

This medicine is commonly used to help with symptoms in conditions involving heightened physiological activity, such as allergic responses, various forms of arthritis, and other disorders affecting the skin, lungs, and eyes. It may assist with managing symptoms that create noticeable physiological strain in contexts involving heightened systemic burden.

Management of Allergic and Immune Flares

It is considered relevant in contexts involving heightened systemic burden, such as those related to allergic and immune responses. This symptomatic assistance supports patients during episodes of heightened discomfort and may assist with maintaining functional stability during periods of acute discomfort.

Quick Fact: Symptom Management

This medication may be part of symptomatic management in conditions characterized by periods of heightened inflammation and swelling.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Dexona?

The eligibility for the topical combination Dexamethasone and Neomycin is strictly defined by regulatory documents, establishing absolute contraindications and population restrictions.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

  • Patients with known or suspected hypersensitivity to Dexamethasone, Neomycin, or any component.
  • Patients with active viral diseases (e.g., Herpes Simplex Keratitis), Mycobacterial infection, or Fungal diseases of the eye or ear.
  • Patients with a perforated tympanic membrane (for otic use).

Conditional Eligibility and Age Limitations

Population Regulatory Eligibility Status
Children Under 2 Years Safety and efficacy have not been established for ophthalmic use.
Glaucoma/Ocular Hypertension Use requires caution and routine monitoring of intraocular pressure (IOP) if used for 10 days or longer.
Corneal/Scleral Thinning Use is restricted due to the increased risk of perforation.
Pregnancy Not recommended; classified as Category C. Use only if benefit justifies potential risk.
Lactation Caution should be exercised; a risk to the suckling child cannot be excluded.

These eligibility rules reflect the standardized regulatory classifications that prohibit use in the presence of specific infections or mandate conditional use and monitoring for patients with pre-existing ocular conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Dexona is strictly based on the documented risks associated with the potential for low-level systemic absorption of its two active ingredients, Dexamethasone and Neomycin. All documented interactions relate to drug-drug co-administration scenarios and highlight specific population constraints.


Pharmacokinetic and Exposure-Altering Interactions

The Dexamethasone component is metabolically sensitive to co-administered substances. Co-treatment with strong CYP3A inhibitors, such as ritonavir or cobicistat, is expected to increase Dexamethasone plasma concentrations. This pharmacokinetic interaction is officially documented because it raises the risk of systemic corticosteroid effects, including the potential for adrenal suppression. Regulatory information advises caution when these combinations are used.


Pharmacodynamic Interactions and Special Precautions

The Neomycin component may contribute to additive effects when co-administered with certain other medicines. This includes the potential to potentiate the effects of neuromuscular blocking agents through pharmacodynamic action. A crucial population-specific interaction note highlights a constraint: in patients with a perforated tympanic membrane, systemic absorption of Neomycin is higher. This increased exposure elevates the risk of adverse interactions with other ototoxic or nephrotoxic agents. Regulatory documents do not list absolute drug-drug contraindications or administration timing requirements for this topical formulation, nor do they specify interactions with food, alcohol, or herbal products.

Mechanism of Action

Dexamethasone is a synthetic glucocorticoid that operates primarily through the glucocorticoid receptor (GR). This lipophilic molecule readily diffuses across the cell membrane and binds to the inactive cytosolic GR complex, causing it to translocate to the nucleus.

In the nucleus, the activated GR dimer binds to specific DNA sequences known as glucocorticoid response elements (GREs), leading to transactivation (increased transcription) of anti-inflammatory genes. Simultaneously, the GR interferes with pro-inflammatory transcription factors, such as NF-kappa B (NF-κB) and AP-1, through transrepression. This dual genomic action suppresses the expression of numerous pro-inflammatory genes, including those coding for cytokines (e.g., IL-1, IL-6), chemokines, and inducible enzymes (e.g., COX-2).

Mechanistically, Dexamethasone also induces the synthesis of lipocortin-1 (annexin A1), which inhibits phospholipase A2 (PLA₂). This comprehensive modulation results in decreased cellular recruitment and diminished synthesis of inflammatory mediators. Additionally, it influences the hypothalamic-pituitary-adrenal (HPA) axis via negative feedback, suppressing endogenous cortisol secretion.

Dosage and Administration Information

Administration and Dosing Instructions

Dexona (dexamethasone) is administered through multiple routes, including oral (tablet, solution, or concentrate) and parenteral injection (intravenous [IV], intramuscular [IM], intra-articular, soft tissue, or intralesional). The official instructions emphasize that the dosage must be individualized based on the severity of the condition being treated and the patient's response.

Official Dosing Rules

Treatment is initiated with a specific dose, which should be maintained or adjusted until a satisfactory response is noted. The dose must then be gradually reduced to the lowest effective level. For oral use, initial adult doses typically range from 0.75 mg to 9 mg daily, which may be given in divided doses. Pediatric dosing is also highly variable and may be divided and taken 3 or 4 times a day.

Preparation and Special Conditions

For the oral solution concentrate, the dose must be measured precisely using the provided dropper, mixed well with a beverage or soft food (such as water, juice, or applesauce), and the entire mixture must be consumed immediately; it should not be stored for later use.

If a patient on corticosteroid therapy is subjected to unusual stress (e.g., surgery, trauma, or severe illness), the dosage may need to be temporarily increased. Discontinuation of therapy, particularly after prolonged use, requires a gradual reduction in dosage.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dexona


Evidence for Use in Acute External Ear Conditions (Otitis Externa)

Research exploring the use of topical anti-inflammatory and anti-infective combinations, such as those containing Dexamethasone and Neomycin, largely involves Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted during periods of increased symptom activity in patients with conditions where studies explored symptoms and signs related to inflammation and infection of the external ear canal. The findings describe patterns observed in the studies where the addition of the steroid component was associated with observed differences in the rate of resolution of inflammatory signs when compared to antibiotic-only treatments.

Evidence for Use in Inflammatory Eye Conditions with Risk of Infection

Research regarding the combination's use in steroid-responsive inflammatory ocular conditions (such as certain types of conjunctivitis or corneal inflammation) involves studies focusing on episodes where symptoms become more noticeable. Study outcomes examined included objective measures of ocular inflammation (such as redness and edema scores) and microbiologic outcomes. However, data for the specific Dexamethasone/Neomycin dual combination is frequently considered within the context of related triple-combination products (often including Polymyxin B).

Long-Term Studies and Follow-Up Data

Research exploring short-term symptom changes is most relevant for this medication, given that the treated conditions are generally acute or episodic. In the clinical trials for both ear and eye conditions, follow-up durations were typically limited to the period needed to confirm clinical resolution, often less than 30 days. Due to this focus on acute treatment, there is limited information for long-term outcomes, and the research does not extensively characterize the durability of symptom control.

Research Gaps and Areas of Uncertainty

The research contributes to the broader evidence landscape but also highlights key areas where certainty remains low. One limitation is the reliance on studies of analogous combination products; the evidence for Dexamethasone/Neomycin sometimes draws on data that included a third active component; consequently, the exact contribution of the dual formulation is often not specifically isolated.

Key Studies & References

  1. Systematic review of topical antimicrobial therapy for acute otitis externa
  2. Ophthalmic Antibiotic–Steroid Combinations Therapeutic Class Review (TCR) - HHS/Magellan Rx Management

Frequently Asked Questions (FAQ)

Common questions about Dexona (FAQ)

Q: How is Dexona different from the body's natural hormones?

Dexona contains Dexamethasone, which is a synthetic substance classified as a glucocorticoid. This means the drug is chemically manufactured to mimic the action of cortisol, a hormone naturally produced by the body. The official product information indicates it works by regulating many processes normally controlled by these natural hormones, specifically targeting inflammation.

Q: Does Dexona treat specific diseases or mainly the symptoms of inflammation?

According to regulatory documents, Dexamethasone is prescribed for a wide range of conditions, including certain types of cancer, inflammation, and allergies. Its primary action is to relieve symptoms like swelling and redness by acting on the immune system to suppress inflammation. The way the drug is used varies significantly based on the specific condition being managed.

Q: Why does taking Dexona often cause weight gain or increased appetite?

Official information states that weight gain is a possible side effect of systemic Dexamethasone, particularly when used for long periods. This increase is often related to a drug-induced rise in appetite and the tendency of the medication to cause the body to retain salt and water, which is known as fluid retention or edema.

Q: Is 'moon face' a common or temporary side effect associated with Dexona use?

The feature described as 'moon face' (facial rounding) is a recognized sign of systemic steroid effects and is officially classified as a possible adverse reaction. This and other changes in fat distribution (Cushingoid features) are more commonly observed with high doses or prolonged courses of therapy.

Q: How long do the mental side effects of Dexona, like mood swings, typically last?

Regulatory documents note that Dexamethasone can be associated with psychiatric changes, including mood swings, irritability, and anxiety. The official product information indicates that most psychiatric reactions are reported to resolve following dosage modification or discontinuation of the medication.

Q: Can Dexona cause difficulty sleeping or change my usual sleep patterns?

Yes, difficulty sleeping (insomnia) is listed in official prescribing information as a common side effect affecting the central nervous system. This is an expected effect for systemic corticosteroids.

Q: Is it true that Dexona can affect blood sugar levels, even for people without diabetes?

Official regulatory sources indicate that Dexamethasone can cause hyperglycemia, which means high blood sugar levels. This can happen even in people who do not have a diagnosis of diabetes. The medication is noted to impair the body’s ability to process carbohydrates, which may require monitoring.

Q: Are skin changes, such as thinning or acne, described as side effects of using Dexona?

Official documents list dermatologic changes as possible side effects. These include the development of acne, thinning and increased fragility of the skin, increased sweating, and the formation of stretch marks (striae).

Q: Can Dexona cause fluid retention or swelling in the feet and ankles?

Yes, the official product information states that fluid retention (edema) is a possible side effect. This occurs because the medication can cause the body to retain sodium and water, which are classified as fluid and electrolyte disturbances.

Q: Is there a recognized connection between Dexona use and changes in blood pressure?

Regulatory warnings state that the systemic use of this type of medication can lead to an elevation of blood pressure. Therefore, official documents advise caution and monitoring for patients who have pre-existing high blood pressure or other heart-related conditions.

Q: What are the common gastrointestinal side effects reported for Dexona?

Common gastrointestinal side effects reported in official documents include dyspepsia (indigestion), nausea, vomiting, and abdominal bloating. More seriously, there is a potential risk for the development of peptic ulcers, which could lead to perforation or bleeding.

Q: Are headaches a frequently reported side effect when taking this medication?

Yes, official product information lists headache as a recognized neurological side effect associated with the systemic use of this medication.

Q: What is the risk of developing weaker bones (osteoporosis) from long-term Dexona use?

Studies and official documentation indicate that long-term systemic use is associated with a risk of developing osteoporosis, a condition characterized by weaker bones. There is also a noted risk of fractures, including breaks in long bones and vertebral compression fractures.

Q: What are the signs of adrenal gland problems linked to stopping Dexona use?

Signs of adrenal gland problems, specifically adrenal insufficiency after stopping the drug, are officially recognized. These signs may include severe fatigue, muscle weakness, a decreased appetite, weight loss, severe vomiting, or feeling severely dizzy.

Q: Does Dexona lower the body's natural ability to fight off infections?

According to regulatory documents, systemic corticosteroids can increase the body's susceptibility to infections. The medication may also suppress the body's response, potentially masking the usual signs and symptoms of an existing infection. Official warnings note that avoiding exposure to certain viral diseases, such as chickenpox and measles, is important for patients taking this drug.

Q: Is there a recognized risk of muscle weakness or muscle pain with Dexona?

Muscle weakness is a recognized side effect that is documented in official sources as a musculoskeletal adverse reaction. This can sometimes be accompanied by muscle pain and a loss of muscle mass (myopathy).

Q: How often are serious mood changes, like severe depression or anxiety, reported?

Official product information notes that psychiatric reactions are common and may occur in both adults and children taking this drug. The frequency of more serious reactions, which include severe depression, anxiety, and psychotic reactions, has been estimated in adults to occur in 5% to 6% of cases.

Q: What types of infections are patients on Dexona generally advised to be cautious about?

Official documents advise that patients should be especially cautious of exposure to certain viral diseases like chickenpox and measles. Furthermore, the drug is officially contraindicated (should not be used) in patients with active fungal infections or certain viral diseases.

Q: Does long-term use of Dexona affect a patient's thyroid function?

Official documents indicate that glucocorticoids can affect the body's endocrine system, which includes the thyroid. The drug is known to suppress Thyrotropin (TSH) levels in the blood, which may alter overall thyroid hormone levels. This means caution is required for people with pre-existing thyroid conditions.

Q: What are the described effects of Dexona on the heart and circulatory system?

Regulatory warnings state that the drug can cause fluid retention and elevated blood pressure. In susceptible patients, this may lead to or worsen congestive heart failure. The official labeling also notes that myocardial rupture (a tear in the heart muscle) has been reported in rare instances following a recent heart attack.

Q: Can Dexona cause stomach ulcers or digestive tract issues?

Yes, official product information lists the risk of peptic ulcers as a serious potential side effect, which could potentially lead to perforation or bleeding (hemorrhage). Due to this risk, the drug should be used with particular caution in patients who have a history of stomach or peptic ulcers.

Q: What happens in the body when a person stops taking Dexona suddenly?

Regulatory warnings state that if the dosage is reduced too quickly after prolonged use, it can lead to acute adrenal insufficiency. This is a serious condition that can cause low blood pressure (hypotension). Additionally, a 'withdrawal syndrome' marked by symptoms like fever and muscle pain may occur.

Q: Is Dexona typically used for short-term 'bursts' or for longer-term therapy?

Official documents emphasize that Dexamethasone should be used at the lowest effective dose for the minimum possible duration. The detailed side effect profiles, which include risks like bone thinning and Cushingoid features, are noted to be more likely with prolonged or long-term therapy.

Q: Is it necessary for the dosage of Dexona to be gradually reduced over time?

Yes, regulatory documents state that a gradual reduction in dosage is necessary when discontinuing therapy, especially after the medication has been used for a prolonged period. This process helps prevent the serious adverse effect of acute adrenal insufficiency.

Q: Are there common over-the-counter pain relievers that may interact with Dexona?

Regulatory sources note a specific interaction with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common over-the-counter pain relievers. The co-administration of these drugs may increase the risk of gastrointestinal side effects, including peptic ulceration and internal bleeding.

Q: Is alcohol consumption generally discouraged while a person is taking Dexona?

While the drug label does not strictly prohibit alcohol, official guidance notes that consumption of alcohol should be approached with caution when taking systemic corticosteroids. This is due to a potential increase in stomach irritation and the risk of gastrointestinal issues, especially since Dexamethasone carries an independent risk of ulcers.

Q: Does Dexona interact with certain vitamin or herbal supplements?

Official information advises that patients should tell their prescribing physician about all supplements and herbal products they are taking. This is particularly important for products that can influence the CYP3A4 enzyme system in the body, which can potentially alter the concentration of Dexamethasone in the blood.

Q: Are there known interactions between Dexona and prescription medications for diabetes?

Yes, official product information indicates that Dexamethasone can interfere with the body's ability to control blood glucose levels. This means that the drug may reduce the effectiveness of insulin and other prescription medications used to treat diabetes, and dosage modification may be necessary, according to official labeling.

Q: Can people with a history of ulcers or stomach problems use Dexona?

Official documents state that use requires caution in patients with a history of stomach or peptic ulcers. The drug can aggravate these conditions and increase the risk of gastrointestinal bleeding or perforation.

Q: Is Dexona use restricted for people with pre-existing heart conditions, like heart failure?

Yes, official warnings advise that the drug must be used with caution in patients who have pre-existing heart conditions, such as heart failure or high blood pressure. This is because the drug can cause the body to retain sodium and water, which could worsen these conditions.

Q: Are there special considerations for elderly patients taking Dexona?

Yes, official product information acknowledges that elderly patients may be more susceptible to the side effects of corticosteroids. Specifically, there is an increased risk of issues like osteoporosis and potential complications due to age-related changes in organ function, which may require careful monitoring.

Q: Can Dexona affect the growth of children or teenagers if taken long-term?

Regulatory documents explicitly state that long-term systemic use in children and adolescents can affect the endocrine system. This administration may lead to growth suppression and premature epiphyseal closure, which is the official term for stunted growth.

Q: Are people with a history of mental health issues advised against taking Dexona?

Official regulatory warnings state that particular care is required when considering the use of this drug in patients with an existing or previous history of severe psychiatric or affective disorders. This includes conditions such as depression, mania, or psychosis.

Q: What are the warnings about using Dexona if a patient has a history of high blood pressure?

Regulatory documents warn that average and large doses of the medication can cause an elevation of blood pressure. Therefore, official labeling indicates that caution and careful monitoring are necessary when the drug is used in patients with pre-existing hypertension (high blood pressure).

Q: Why is Dexona often administered alongside certain chemotherapy treatments?

Dexamethasone is approved for use in certain blood-related cancers and is often incorporated into treatment protocols. Additionally, it is used alongside chemotherapy to help manage common side effects of those treatments, such as severe nausea or swelling.

How should Dexona be stored and disposed of?

How to Store and Dispose of Dexona?

Official regulatory documents define strict storage and disposal requirements for Dexona (Dexamethasone/Neomycin ophthalmic/otic solution) to ensure product integrity and safety.


Storage Requirements

The solution must be stored within a temperature range of 8 C to 27 C (46 F to 80 F) and must not be frozen. The container must be kept tightly closed, protected from light, and stored in an upright position. To prevent contamination, avoid touching the dropper tip to any surface. For safety, this prescription medication must be stored out of the sight and reach of children.


Stability and Disposal

Once the bottle is opened, the solution must be discarded after 28 days. Disposal of any unused or expired solution must be managed according to local requirements. Medications should not be flushed down the toilet or poured into a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexona found in:

A-Z Index: